RenovoRx (RNXT) announced that Johns Hopkins Medicine is now initiated to enroll patients with locally advanced pancreatic cancer in the ongoing Phase III TIGeR-PaC clinical trial. The trial is evaluating RenovoRx’s intra-arterial delivery of gemcitabine via the RenovoCath device. Johns Hopkins Medicine’s Valerie Lee was appointed Principal Investigator for the site. RenovoRx expects full enrollment in the trial during 2025.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RNXT:
- RenovoRx Reports Initial Revenue and Clinical Trial Progress
- RenovoRx increases production of RenovoCath
- RenovoRx: Promising Phase 3 Study and Revenue Growth Drive Buy Rating
- RenovoRx Delays Yearly Report Filing
- RenovoRx’s Innovative Approach to Pancreatic Cancer Treatment: A Promising Investment Opportunity